sanofi-aventis Pakistan limited

INTERIM CONDENSED FINANCIAL STATEMENTS FOR THE FIRST QUARTER ENDED MARCH 31, 2009

(UN-AUDITED)

sanofi aventis

Because health matters

CONTENTS

	Pages
Company Information	2
Directors' Report	3
Statement of Financial Position	4
Statement of Comprehensive Income	5
Statement of Cash Flows	6
Statement of Changes in Equity	7
Notes to the Financial Statements	8

COMPANY INFORMATION

Board of Directors

Syed Babar Ali Tariq Wajid Pir Ali Gohar Tariq Iqbal Khan Syed Hyder Ali J.L. Grunwald Eric Le-Bris Jean-Marc Georges M.Z. Moin Mohajir Chairman Managing Director (Alternate Arshad Ali Gohar)

(Alternate Dr.Amanuallah Khan) (Alternate Shakeel Mapara) (Alternate Muhammad Amjad)

Company Secretary Muhammad Irfan

Board Audit Committee

Syed Hyder Ali Eric Le-Bris Dr. Amanullah Khan

Yasir Pirmuhammad

(Chairman) Non-Executive Director (Member) Non-Executive Director (Member) Executive Director

(Secretary) Head of Audit & Compliance

Board Share Transfer Committee

Tariq Wajid M.Z. Moin Mohajir

Management Committee

Tariq Wajid Muhammad Amjad Dr. Amanullah Khan Zubair Rizvi Aslam Sheikh Masaud Ahmed Dr. Sohail Manzoor M.Z. Moin Mohajir Shakeel Mapara Aamer Waheed Masood A. Khan Yasir Pirmuhammad Mamoona F. Naqvi Laila Khan

Auditors

Ford Rhodes Sidat Hyder & Co. Chartered Accountants

Legal Advisors

Azfar & Azfar Haidermota & Co. Saadat Yar Khan & Co. Ghani Law Associates Bilal Law Associates Syed Qamaruddin Hassan Kundi & Kundi

Registered Office

Plot 23, Sector 22, Korangi Industrial Area, Karachi - 74900

Registrars & Share Transfer Office

FAMCO Associates (Pvt.) Ltd. State Life Building No. 2-A, I.I. Chundrigar Road, Karachi - 74000.

Bankers

Citibank, N.A.
Deutsche Bank AG
Habib Bank Ltd.
MCB Bank Ltd.
Standard Chartered Bank
The Royal Bank of Scotland Ltd.

Postal Address

P.O. Box No. 4962, Karachi - 74000

URI

www.sanofi-aventis.com.pk

DIRECTORS' REPORT TO THE SHAREHOLDERS

We are pleased to present the un-audited interim condensed financial statements of your company, for the quarter ended March 31, 2009. These financial statements have been prepared in accordance with section 245 of the Companies Ordinance, 1984.

Net sales for the period under report, at Rs.1,185 million, recorded a healthy growth of 35.49% over the comparable period last year. As mentioned in our earlier reports also, the growth in net sales is mainly attributable to volume growth as we were granted price increases for "hardship cases", in the last week of November 2008, on 4 products only, with the freeze on selling prices since December 2001 continuing on the remaining products. The sales growth above also included net sales for vaccines private market business which, as mentioned in our last report, has started functioning during the quarter under report and is expected to add more value during the remaining quarters of the year ending December 31, 2009.

Gross margin as a percentage of net sales has reduced to 24.16% from 27.16% over the comparative prior period. The decrease in margins is mainly due to depreciation of Pak Rupee against all hard currencies resulting in higher cost of raw and packing materials, continued high inflation as well as significant increases recorded in all cost categories.

Distribution and marketing expenses have increased by 34.14% as compared to the comparative period last year; however, as a % of net sales these have reduced from 21.97% to 21.75%. The cost increase in absolute terms is mainly attributable to general inflation and increase in spending on advertising and promotional activities necessary to invest in core and new products. Administrative expenses increased by 26% over the corresponding period last year, again mainly due to general inflation.

Operating income for the period includes gain on disposal of freehold land and building, located at Rawalpindi, for an amount of Rs.49.63 million classified as non-current assets held for sale as at December 31, 2008. Finance cost increased by 108.20% over the similar period last year, due to capital expenditure and high borrowing costs in the preceding months.

Profit before tax for the quarter ended has reduced by Rs.11.439 million over the comparative prior period because of the reasons explained above.

We launched Apidra® SoloSTAR® (insulin glusine) to help patients with Type I and Type II diabetes to achieve their treatment targets. Lantus® SoloSTAR® and Apidra® SoloSTAR® is the best combination of insulin and easy to use pen that's easier to inject.

Notwithstanding unforeseen events, we expect the sales growth in the remaining quarters of 2009 to be in line with the industry trend. However, due to adverse impact of devaluation of Pak Rupee and inflation, across the board price increase is now essential for the Pharma industry. Industry representatives are in constant engagement with the relevant government officials for this purpose.

On behalf of the Board of Directors, we would like to acknowledge the hard work put in by all the employees of the Company.

By order of the Board

SYED BABAR ALI

Chairman

TARIQ WAJID Chief Executive

INTERIM CONDENSED STATEMENT OF FINANCIAL POSITION

AS AT MARCH 31,2009

	Note	March 31, 2009	December 31, 2 0 0 8
			s in '000(Audited)
ASSETS		(Un-audited)	(Auditeu)
NON-CURRENT ASSETS			
Fixed assets Property plant and equipment Intangible asset Long-term loans Long-term deposits	4	1,305,986 566 5,765 3,509	1,195,249 729 6,361 3,325
CURRENT ASSETS Stores and spares Stock-in-trade Trade debts Short term loans and advances Trade deposits and short-term prepayments Other receivables Taxation – payment less provision Cash and bank balances		40,522 1,196,416 140,811 26,199 111,734 83,749 294,759 7,959 1,902,149	40,912 1,104,944 151,951 24,188 40,585 135,252 269,802 2,186 1,769,820
NON-CURRENT ASSETS CLASSIFIED AS HELD FO	RSALE	-	8,871
TOTAL ASSETS		3,217,975	2,984,355
SHARE CAPITAL AND RESERVES Share capital Authorised 10,000,000 Ordinary shares of Rs.10 each		100,000	100,000
Issued, subscribed and paid-up		96,448	96,448
Reserves Capital reserves Revenue reserve		50,318 975,903 1,026,221	48,255 971,909 1,020,164
NON-CURRENT LIABILITY Deferred taxation		1,122,669 56,906	1,116,612 70,147
CURRENT LIABILITIES Trade and other payables Accrued mark-up on short term borrowings Short-term borrowings		905,574 30,202 1,102,624	892,998 32,086 872,512
CONTINGENCIES AND COMMITMENTS		2,038,400	1,797,596
		3,217,975	2.984.355
TOTAL EQUITY AND LIABILITIES		3,211,313	2,504,500

The annexed notes 1 to 11 form an integral part of these interim condensed financial statements.

SYED BABAR ALI

Chairman

TARIQ WAJID Chief Executive

INTERIM CONDENSED STATEMENT OF COMPREHENSIVE INCOME FOR THE FIRST QUARTER ENDED MARCH 31,2009 (UN-AUDITED)

	March 31, 2009	March 31, 2008
	Rupees	in '000 (Restated)
NET SALES	1,185,439	874,922
Cost of sales	(899,037)	(637,263)
GROSS PROFIT	286,402	237,659
Distribution and marketing expenses	(257,784)	(192,178)
Administrative expenses	(34,209)	(27,149)
Other operating expenses	(9,493)	(2,642)
Other operating income	56,381	21,504
Proposition and the second sec	(245,105)	(200,465)
OPERATING PROFIT	41,297	37,194
Finance costs	(32,653)	(17,111)
PROFIT BEFORE TAXATION	8,644	20,083
Taxation - Current for the period	(3,820)	(14,385)
- Deferred	12,673	3,431
	8,853	(10,954)
NET PROFIT FOR THE PERIOD	17,497	9,129
OTHER COMPREHENSIVE INCOME - net of tax		
Employee benefit cost under IFRS 2 – "Share based Payment"	2,063	334
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD	19,560	9,463
BASIC EARNINGS PER SHARE (Rs. per share)	1.81	0.95

The annexed notes 1 to 11 form an integral part of these interim condensed financial statements.

SYED BABAR ALI

Chairman

TARIQ WAJID Chief Executive

INTERIM CONDENSED STATEMENT OF CASH FLOWS

FOR THE FIRST QUARTER ENDED MARCH 31,2009 (UN-AUDITED)

	Note	March 31, 2 0 0 9 Rupees	March 31, 2 0 0 8 in '000 (Restated)
CASH FLOWS FROM OPERATING ACTIVITIES			
Cash (used in) / generated from operations Finance costs paid Income tax paid Long-term loans (net) Long-term deposits (net)	6	(80,918) (34,537) (29,345) 596 (184)	32,306 (32,847) (24,015) 1,867
Net cash used in operating activities		(144,388)	(22,689)
CASH FLOWS FROM INVESTING ACTIVITIES			
Capital expenditure Sale proceeds from disposal of operating fixed assets Sale proceeds from disposal of non-current assets classified as held for sale		(142,656) 5,535 58,500	(40,863) 5,842
Net cash used in investing activities		(78,621)	(35,021)
CASH FLOWS FROM FINANCING ACTIVITIES			
Dividends paid		(1,330)	74
NET DECREASE IN CASH AND CASH EQUIVALENTS		(224,339)	(57,710)
CASH AND CASH EQUIVALENTS AT BEGINNING OF THE PER	HOD	(870,326)	(540,083)
CASH AND CASH EQUIVALENTS AT END OF THE PERIOD	7	(1,094,665)	(597,793)

The annexed notes 1 to 11 form an integral part of these interim condensed financial statements.

SYED BABAR ALI

Chairman

TARIQ WAJID Chief Executive

INTERIM CONDENSED STATEMENT OF CHANGES IN EQUITY FOR THE FIRST QUARTER ENDED MARCH 31,2009 (UN-AUDITED)

			Capital Reserves		Reven	ue Reserves	
	Issued, subscribed and paid-up share capital	Long term liabilities forgone	Difference of share capital under scheme of arrangement for amalgamation	Other	General reserve	Unappropriated profit	Total
	**********		Ru	pees in '000)		
Balance as at January 1, 2008	96,448	5,935	18,000	17,036	835,538	141,167	1,114,124
Total comprehensive income for period ended March 31, 2008	the -	4	÷	334	5	9,129	9,463
Final dividend for the year ended December 31, 2007	4 4	12	2	12	12	(42,437)	(42,437)
Transfer to general reserve	12	74	12	÷	100,000	(100,000)	-
Balance as at March 31, 2008	96,448	5,935	18,000	17,370	935,538	7,859	1,081,150
Balance as at January 1, 2009	96,448	5,935	18,000	24,320	935,538	36,371	1,116,612
Total comprehensive income for period ended March 31, 2009	the -	2	5	2,063		17,497	19,560
Final dividend for the year ended December 31, 2008			1.52		.5	(13,503)	(13,503)
Balance as at March 31, 2009	96,448	5,935	18,000	26,383	935,538	40,365	1,122,669

The annexed notes 1 to 11 form an integral part of these interim condensed financial statements.

SYED BABAR ALI

Chairman

TARIQ WAJID Chief Executive

NOTES TO THE INTERIM CONDENSED FINANCIAL STATEMENTS

FOR THE FIRST QUARTER ENDED MARCH 31,2009 (UN-AUDITED)

1. THE COMPANY AND ITS OPERATIONS

The Company was incorporated in Pakistan in 1967 under the Companies Act, VII of 1913, as a Public Limited Company. The shares of the Company are listed on Karachi, Lahore and Islamabad Stock Exchanges. It is currently engaged in the manufacturing and selling of pharmaceutical products.

The registered office of the Company is located at Plot 23, Sector 22, Korangi Industrial Area, Karachi.

2 BASIS OF PREPARATION

These interim condensed financial statements are unaudited and are being submitted to the shareholders as required under Section 245 of the Companies Ordinance, 1984 and the Listing Regulations of Karachi, Lahore and Islamabad Stock Exchanges and have been prepared in accordance with the requirements of the International Accounting Standard (IAS) – 34 "Interim Financial Reporting", as applicable in Pakistan.

The interim condensed financial statements do not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Company's annual financial statements for the year ended December 31, 2008.

3. SIGNIFICANT ACCOUNTING POLICIES

The accounting policies adopted in the preparation of these interim condensed financial statements are the same as those applied in the preparation of the annual financial statements of the Company for the year ended December 31, 2008.

Accounting standards, amendments and interpretations effective in 2009

IAS1, "Presentation of financial statements", issued in September 2007 revises the existing IAS 1 and is effective from January 1, 2009. It requires apart from changing the names of certain components of financial statements, presentation of transactions with owners in the statement of changes in equity and with non-owners in the comprehensive income statement. Adoption of revised standard mainly impacts the presentation of the financial statements.

	Note	March 31, 2 0 0 9	December 31, 2 0 0 8
	,,,,,,	(Un-audited)	s in '000(Audited)
 PROPERTY, PLANT AND EQUIPMENT – at cost Operating fixed assets Capital work-in-progress 	4.1	633,427 672,559 1,305,986	644,858 550,391 1,195,249

4.1 Operating fixed assets

Following were the additions and disposals of fixed assets during the current period:

		ī	Disposals	
	Additions	Cost	Accumulated Depreciation	
		Rupees in '000		
		2.043	1,570	
Plant and machinery Furniture and fixtures	40	2,040		
Factory and office equipments	6,623	3,416	1,405	
Vehicles	13,825	3,877	2,700	

NOTES TO THE INTERIM CONDENSED FINANCIAL STATEMENTS

FOR THE FIRST QUARTER ENDED MARCH 31,2009 (UN-AUDITED)

5. CONTINGENCIES AND COMMITMENTS

Contingencies

- 5.1 Bank guarantees, aggregating to Rs.74.338 million, as at March 31, 2009 (December 31, 2008: Rs.69.328 million) have been given to the Collector of Customs in respect of exemption of levies on import of specified pharmaceutical materials subject to the consumption of such raw materials within the specified period and to various other parties.
- 5.2 There is no change in the status of other contingencies, as set out in note 21.1 to the annual financial statements of the Company for the year ended December 31, 2008.

Commitments

- 5.3 Commitments in respect of capital expenditure contracted for as at March 31, 2009 amounted to Rs.121.530 million (December 31, 2008: Rs.209.76 million).
- 5.4 Commitments for rentals under operating lease agreements in respect of vehicles as at March 31, 2009 amounted to Rs.2.381 million (December 31, 2008: Rs.3.520 million), payable over the next three years as follows:

Years		March 31, 2009	December 31 2008
		Rupee	s in '000
2009		1,496	2458
2010		708	708
2011		177	354
		2,381	3,520
		March 31,	March 31,
	Note	2009	2008
		Rupee	s in '000
			(Restated)

6. CASH GENERATED FROM OPERATIONS

Profit before taxation		8,644	20,083
Adjustment for non-cash charges and other items:			
Depreciation / amortization		28,421	25,646
Gain on disposal of operating fixed assets		(1,874)	(3,505)
Gain on disposal of non-current assets classified as held for sale		(49,629)	
Expenses arising from equity settled share based plans		2,063	334
Retirement benefits		2,530	2,175
Financial charges		32,653	17,111
Working capital changes	6.1	(103,726)	(29,538)
Secretary and development to develop the secret		(80,918)	32,306

NOTES TO THE INTERIM CONDENSED FINANCIAL STATEMENTS

FOR THE FIRST QUARTER ENDED MARCH 31,2009 (UN-AUDITED)

March	31,	March 31,
200	9	2008
*******	Rupees in	1 '000

(Restated)

6.1 Working capital changes

Decrease / (increase) in current assets:

Stores and spares	390	(1,309)
Stock-in-trade	(91,472)	13,939
Trade debts	11,140	13,924
Short-term loans and advances	(2,011)	(8,747)
Trade deposits and short-term prepayments	(71,149)	(2,643)
Other receivables - net	52,017	8,152
	(101,085)	23,316

(Decrease) in current liabilities:

Trade and other payables – net		
(excluding accruals for financial charges and unclaimed dividend)	(2,641)	(52.854)
	(103,726)	(29,538)

7. CASH AND CASH EQUIVALENTS

Cash and cash equivalents comprise of the following items:

Cash and bank balances	7,959	3,392
Short-term borrowings	(1,102,624)	(601,185)
CONTRACTOR AND A SECURITY OF A	(1,094,665)	(597,793)

8. TRANSACTIONS WITH RELATED PARTIES

Related parties comprise of associated undertakings, employees' provident fund, employees' gratuity fund, employees' pension fund, directors and key management personnel of the Company.

There are no transactions with key management personnel other than under the terms of employment.

Details of transactions with related parties during the period were as follows:

		March 31, 2009				March 31, 2008					
		Group Companies	Related parties by virtue of common Directorship	Retire- ment benefits plans ses in '00	Key manage- ment personnel	Total	Group Companies	Related parties by virtue of common Directorship	Retire- ment benefits plans sees in '00	Key manage- ment personnel	Total
0	Net sales	6.691	1,520	+	-	8,211	7,672	1,054			8,726
iii	Purchase of goods	262,071	1,993		4	264,064	287,824	9,058	**		295,882
10)	Purchase of services	685	3,858		-	3,858	35	3,096			3,096
W)	Recovery of service charges										4.004
	and other expenses		1,253		-	1,253		1,581	*	5 4	1,581
V2	License fee of land received	240	1,443	-	-	1,443		1,140			1,140
vi)	Royalty and technical fee				*		5,503		**	36	5,503
vii)	Contribution paid										
	- Provident Fund			4,922	-	4,922			4,392		4,392
viii)	Remuneration of key management personnel		4		18,199	18,199	-		45	13,390	13,390

Further, the impact of benefits available to the Chief Executive and others recognized by the Company in the expenses during the period on account of share-based payment plans aggregate Rs.0.597 (2008: Rs.0.626) million and Rs.1.466 (2008: negative Rs.0.292) million respectively.

NOTES TO THE INTERIM CONDENSED FINANCIAL STATEMENTS FOR THE FIRST QUARTER ENDED MARCH 31,2009 (UN-AUDITED)

9. DATE OF AUTHORISATION FOR ISSUE

These interim condensed financial statements were authorized for issue on April 22, 2009 by the Board of Directors of the Company.

10. COMPARATIVE FIGURES

Prior period figures have been rearranged as follows for the purpose of comparison for better presentation:

From To March 31, 2008 --- Rs. in '000 ---

Finance costs

Exchange losses - net

Other operating expenses
Exchange losses - net

2,518

11. GENERAL

Figures presented in these interim condensed financial statements have been rounded off to the nearest thousand rupees.

SYED BABAR ALI

Chairman

TARIQ WAJID Chief Executive

Book Post Under certificate of Posting

If undelivered please return to:

sanofi-aventis Pakistan limited Plot NO. 23, Sector No. 22, Korangi Industrial Area, Karachi-74900

POSTAL ADDRESS P.O. Box No. 4962, Karachi-74000